Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: The ETOS observational study

Annals of General Psychiatry

Volumn 12, Issue 1, 2013, Pages

  Roussidis, Andreas ^a   Kalkavoura, Christina ^b   Dimelis, Dimos ^c   Theodorou, Afroditi ^c   Ioannidou, Ina ^c   Mellos, Eleytherios ^d   Mylonaki, Triantafyllia ^c   Spyropoulou, Areti ^c   Yfantis, Andreas ^e  

^a ASTRAZENECA   (United Kingdom)

^b SISMANOGLIO HOSPITAL   (Greece)

^c Aiginition Hospital ^*

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e Center for Mental Health   (Greece)

Author keywords

Antipsychotic; Clinical outcome; Monotherapy; Schizophrenia; Switch

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHOLESTEROL; GLUCOSE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE DURATION; DISORDERS OF CARBOHYDRATE METABOLISM; DROWSINESS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GYNECOLOGIC DISEASE; HIGH SCHOOL GRADUATE; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MENTAL DISEASE; METABOLIC DISORDER; MIDDLE AGED; MONOTHERAPY; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIMPSON-ANGUS SCALE; SOMNOLENCE; STRESS; URBAN POPULATION; VASCULAR DISEASE; WEIGHT GAIN; YOUNG ADULT;

EID: 84890514501     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-12-42     Document Type: Article

References (32)

1. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry 1996, 53(11):1022. 10.1001/archpsyc.1996.01830110060007, 8911225.
2. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004, 2:13. 10.1186/1741-7015-2-13, 421751, 15115547.
3. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006, 67:453-460. 10.4088/JCP.v67n0317, 16649833.
4. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2. 10.1186/1471-244X-10-2, 2817695, 20059765.
5. Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010, 26:501-509. 10.1185/03007990903488670, 20014981.
6. Canadian Psychiatric Association Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005, 50(Suppl 1):7-57. Canadian Psychiatric Association.
7. Cooper D, Moisan J, Grégoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007, 68:818-825. 10.4088/JCP.v68n0601, 17592904.
8. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK,. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223. 10.1056/NEJMoa051688, 16172203, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
9. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003, 54:719-723.
10. Karagianis J, Williams R, Davis L, Procyshyn R, Monga N, Hanley J, Chandrasena R, Thakur A, Dickson R. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. Curr Med Res Opin 2009, 25:2121-2132. 10.1185/03007990903102966, 19601707.
11. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010, 176:109-113. 10.1016/j.psychres.2009.05.004, 20185182.
12. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2010, 71(Suppl 2):20-26. 10.4088/JCP.9096su1cc.04, 21190649.
13. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007, 115:260-267. 10.1111/j.1600-0447.2006.00982.x, 17355516.
14. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE, Chen L, Adams DH, Ascher-Svanum H, Buckley PF, Citrome L, Volavka J. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 2009, 70:990-996. 10.4088/JCP.08m04221, 19497244.
15. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008, 8:32. 10.1186/1471-244X-8-32, 2390550, 18447935.
16. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008, 69(Suppl 1):4-17.
17. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 2009, 107(1):22-29. 10.1016/j.schres.2008.09.031, 18993031.
18. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003, 64:580-588. 10.4088/JCP.v64n0514, 12755663.
19. Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 2004, 9:357-364.
20. Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry 2002, 63:931-935. 10.4088/JCP.v63n1011, 12416603.
21. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D,. Study 147 Investigators Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008, 24(1):21-32. Study 147 Investigators.
22. De Nayer A, Windhager E, Irmansyah E, Larmo I, Lindenbauer B, Rittmannsberger H, Platz T, Jones A, Whiteford J, Altman C. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003, 7:59-66.
23. Weiden PJ. Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 2006, 20:104-118.
24. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007, 13:13-24. 10.1097/00131746-200701000-00003, 17242588.
25. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(suppl 1):1-93.
26. Tschoner A, Engl J, Rettenbacher M, Edlinger M, Kaser S, Tatarczyk T, Effenberger M, Patsch JR, Fleischhacker WW, Ebenbichler CF. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 2009, 42(1):29-34. 10.1055/s-0028-1100425, 19153944.
27. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004, 70:1-17.
28. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005, 62:19-28. 10.1001/archpsyc.62.1.19, 15630069.
29. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharm 2007, 22:249-267.
30. Altamura AC, Glick ID. Designing outcome studies to determine efficacy and safety of antipsychotics for 'real world' treatment of schizophrenia. Int J Neuropsychopharmacol 2010, 13(7):971-973. 10.1017/S1461145709991271, 20128954.
31. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, McQuade RD, Nyilas M, Iwamoto T, Crandall DT. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA). Schizophr Res 2006, 84:77-89. 10.1016/j.schres.2005.12.857, 16483745.
32. Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol 2009, 29:26Y32.